Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis

this post hoc analysis evaluated spleen response(defined as percentage of patients who achieved ≥50%reduction from baseline in palpable spleen length) andchange from baseline in spleen length at Weeks 12, 24,and 48. At Week 24, hrQoL was assessed by the percent-age of patients achieving Functional Assessment ofCancer therapy–Lymphoma (FACt-Lym) response(≥6.5-point increase from baseline in FACt-Lym totalscore, the lower limit of the minimum clinically importantdifference [7]) and change from baseline in FACt-Lymtotal score. time from first study dose to date of deathwas used to assess oS.